Literature DB >> 3142340

Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

M Salfinger1, L B Heifets.   

Abstract

The MICs of pyrazinamide (PZA) were determined for Mycobacterium tuberculosis cultivated under different pH conditions in 7H12 liquid medium. Mycobacterial growth was monitored by the radiometric method (BACTEC system; Johnston Laboratories, Inc., Towson, Md.). We observed a predictable eightfold difference between the MICs determined at pH 5.5 and those determined at pH 5.95. The highest MICs for 21 susceptible strains were 50.0 micrograms/ml at pH 5.5 and 400 micrograms/ml at pH 5.95. This eightfold difference enabled us to predict MICs at pH 5.5 from the values observed at pH 5.95. The use of 7H12 broth at pH 5.95 simplified the radiometric PZA susceptibility test by avoiding the addition of acid solutions in the course of cultivation, which was required when the test was performed at pH 5.5. An additional benefit of using pH 5.95 instead of pH 5.5 was that all tested strains grew at pH 5.95, while some of them, especially PZA-resistant strains, did not grow at pH 5.5.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3142340      PMCID: PMC172333          DOI: 10.1128/AAC.32.7.1002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The intracellular activation of pyrazinamide and nicotinamide.

Authors:  G B MACKANESS
Journal:  Am Rev Tuberc       Date:  1956-11

2.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

Authors:  W McDERMOTT; R TOMPSETT
Journal:  Am Rev Tuberc       Date:  1954-10

3.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli.

Authors:  K Konno; F M Feldmann; W McDermott
Journal:  Am Rev Respir Dis       Date:  1967-03

4.  A simple way of detecting pyrazinamide resistance.

Authors:  E Brander
Journal:  Tubercle       Date:  1972-06

5.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity.

Authors:  W R Butler; J O Kilburn
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

6.  Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Authors:  M Salfinger; F M Kafader
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1987-07

7.  Evaluation of a radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  J J Tarrand; A D Spicer; D H Gröschel
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Radiometric method for testing susceptibility of mycobacteria to pyrazinamide in 7H12 broth.

Authors:  L B Heifets; M D Iseman
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.

Authors:  J M Dickinson; V R Aber; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1977-10

10.  Rapid drug-susceptibility testing of Mycobacterium tuberculosis.

Authors:  D E Snider; R C Good; J O Kilburn; L F Laskowski; R H Lusk; J J Marr; Z Reggiardo; G Middlebrook
Journal:  Am Rev Respir Dis       Date:  1981-04
View more
  55 in total

1.  Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  M Mestdagh; P A Fonteyne; L Realini; R Rossau; G Jannes; W Mijs; K A De Smet; F Portaels; E Van den Eeckhout
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis.

Authors:  A P Davies; O J Billington; T D McHugh; D A Mitchison; S H Gillespie
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

3.  Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.

Authors:  Tsi-Shu Huang; Susan Shin-Jung Lee; Hui-Zin Tu; Wen-Kuei Huang; Yao-Shen Chen; Chung-Kai Huang; Shue-Ren Wann; Hsi-Hsun Lin; Yung-Ching Liu
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 4.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

5.  Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance.

Authors:  Mirko Zimic; Patricia Fuentes; Robert H Gilman; Andrés H Gutiérrez; Daniela Kirwan; Patricia Sheen
Journal:  Tuberculosis (Edinb)       Date:  2011-10-17       Impact factor: 3.131

6.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil.

Authors:  Vívian de F Sumnienski Rodrigues; Maria Alice Telles; Marta Osório Ribeiro; Patrícia Izquierdo Cafrune; Maria Lucia Rosa Rossetti; Arnaldo Zaha
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

7.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

8.  Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection.

Authors:  S M Graham; D J Bell; S Nyirongo; R Hartkoorn; S A Ward; E M Molyneux
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

9.  Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.

Authors:  Tawanda Gumbo; Chandima S W Siyambalapitiyage Dona; Claudia Meek; Richard Leff
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

10.  New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.

Authors:  Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.